title: Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
abstract: OBJECTIVE
  The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab.
  
  
  CONCLUSIONS
  Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.
authors.affiliation: Department of Radiology, Dana-Farber Cancer Institute and Melanoma Disease Center, Dana-Farber/Brigham and Women's Cancer Center, 44 Binney St, Boston, MA 02115, USA.
authors.forename: Kevin N
authors.initials: KN
authors.lastname: O'Regan
authors.forename: Jyothipriya P
authors.initials: JP
authors.lastname: Jagannathan
authors.forename: Nikhil
authors.initials: N
authors.lastname: Ramaiya
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000000981:diagnostic imaging* / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab